7/ -	2	3		0	2
------	---	---	--	---	---

1	Seg
BOX	->-//-

	Please type a plus sign (+) ınside	this	ı
ت				ρ
-		I Indoctho	Dane	

PTO/SB/05 (11-00) Approved for use through 10/31/2002 OMB 0651-0032 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE streets Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1 53(b))

	Attorney Docket No.	390069.401		
	First Inventor	Jeffrey A. Ledbetter		
	Title	BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS		
	Express Mail Label No.	EL 755733415US		

1	To	
+	4 ≅	
	200	
4	Sic	
7	30903	
Т	5	

1. []		hittal Form (e.g., PTO/SB/17) iginal and a duplicate for fee processing)	7.			D-R in duplicate, large table or gram (Appendix)
2. 🛚	Applicant cl	aims small entity status.	8.	\mathbf{x}		d/or Amino Acid Sequence
<u>R</u>	See 37 CFF	•				f applicable, all necessary)
3. 🛭	Specificatio			a.		Readable Form (CRF)
J. M		rrangement set forth below)		a. b.	Specificati	ion Sequence Listing on:
		title of the Invention		₩.		M or CD-R (2 copies); or
	•	ence to Related Applications			ii. 🛭 paper	m of 02 ft (2 00p.00); 0.
		Regarding Fed sponsored R & D		c.		s verifying identity of above copies
		• •		<u> </u>		(ING APPLICATION PARTS
		o sequence listing, a table, er program listing appendix	9.	Π		apers (cover sheet & document(s))
				.	37 CFR 3.73(
	_	of the Invention	1 10	· 📙		s an assignee) Attorney
		ary of the Invention ption of the Drawings (if filed)	111	. []	•	lation Document (if applicable)
	- Detailed De			Н	Information D	` m` i
	- Claim(s)	scription	'2	·- 📙	Statement (ID	
	٠,	the Disclosure	13	. []	Preliminary A	-/
4. 🛭	• , ,	(35 U.S.C. 113) [Total Sheets <u>26</u>]	14	. 🛚		ot Postcard (MPEP 503) ecifically itemized)
_	or Declaration		4-	П	•	•
a	,	executed (original or copy)	15	. []		y of Priority Document(s) rity is claimed)
b		om a prior application (37 CFR 1.63 (d)) tinuation/divisional with Box 18 completed)	10	П		Certification under 35 U.S.C
	. .		10	i. []	•	
i.		TION OF INVENTOR(S) atement attached deleting inventor(s) named in). Applicant must attach form r its equivalent.
	•	•	1,-	, \Box		rits equivalent.
	the prior application, see 37 CFR 1 63(d)(2) and 1.33(b)			· 📙	Other: _	
6. X	6. Application Data Sheet. See 37 CFR 1.76					
18.	If a CONT	NUING APPLICATION OR APPLICATION CL	AININ	G EC	DEIGN DRIORITY	check appropriate how and supply the
requisite	in a CONTI information be	elow and in a preliminary amendment, or in an	Applic	atio	n Data Sheet under	r 37 CFR 1 76:
	Continuation					ms priority from application
Dri	No Prior application information Examiner Group Art Unit:					
For CC	NITINITATIO	n information Examiner	a dier	-ine	ure of the prior a	
declara	For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or					
divisio	nal applicati	on and is hereby incorporated by refe	rence	. Th	e incorporation	can only be relied upon when a
		nadvertently omitted from the submitte				
		19. CORRESPO	NDE	NCE	ADDRESS	
		Correspondence address below			or:	☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐
Firm Na	me					
Address		.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				1
City, Sta	te, Zip					→ 00500
Country				· · ·		PATENT TRADEMARK OFFICE
Telepho	ne		Fax	_		
Name (F	Print/Type)	Stephen J. Rosenman, Ph.D.			egistration No. Attorney/Agent)	43,058
<u> </u>				1/	illorriey/Ageril)	
Signatur	re	Fan My Cossey		D	ate	January 17, 2002
L				-		

Burden Hour Statement This form is estimated to take D 2 hours to complete Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Commissioner for Patents, Box Patent Application, Washington, DC 20231